Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 1997

View Archived Issues

Genetronics develops electroporation therapy drug delivery system

Oralife reports promising results for diagnostic test for tooth decay

LifeCell reports clinical data on AlloDerm

Oncor's Sunrise Amplification Detection System presented

Hybridon issued patent for pent-enoyl-protected nucleotides

Bayer discloses antiretroviral agents

Novel 5-HT uptake inhibitors from Bristol-Myers Squibb

New agents for postmenopausal syndrome described by Lilly

Ono discloses ICE inhibitors

Comparison of aspirin and pentoxifylline for claudication

Piracetam as an adjuvant to language therapy for aphasia

North American Vaccine's acellular pertussis vaccine approved in Sweden

Buckminsterfullerene photodynamically inactivates enveloped viruses

Phase III results for TS-110 in osteoarthritis

Disposition of AR-177

DA-9601 shows promise for IBD

Antiangiogenic effects of flavopiridol

Positive clinical results for mitoxantrone in multiple sclerosis

Canadian clearance for Naropin

Triptorelin + melatonin for prostate cancer

Further launches for LeukoScan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...